Category: Diagnostic imaging
Founders: Jean Pham, Fiona Wang, and Dr. Igor Sokolov
Location: Medford, MA
"What makes bladder cancers so difficult to monitor is because of its high recurrence rate,” said Cellens cofounder Jean Pham during BIOMEDigital. Patients have to go through invasive cystoscopies every three to six months for at least 5 years and then annually after that, it was reported.
As an alternative, Cellens is developing “a high-performing noninvasive bladder cancer detection test,” using just a urine sample, she explained. “When we extract the cells from urine samples, we scan the cell surface and pick up the physical biomarkers and use machine learning algorithms to produce a quantitative score for likelihood of recurrence,” she explained. Cellens has demonstrated 94% accuracy, which is significantly higher than the current clinical standard of cystoscopy, of just 70%, she said.
The company is raising money to help go through a pilot study with hospital partners, Pham said.